R(+)-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors

Nieri, Paola; Martinotti, Enrica; Testai, Lara; Adinolfi, Barbara; Calderone, Vincenzo; Breschi, Maria Cristina

doi:10.1016/s0014-2999(02)02831-5

Cited by 10 publications

(5 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many of these effects are rimonabant insensitive and rather involve vanilloid or CB 2 receptors. Thus, inhibition of the electrically induced contraction of the guinea pig trachea is vanilloid-receptor mediated (Nieri et al 2003), whereas the sensory nerve-related activation of the guinea pig and human vagus nerve (Patel et al 2003) or the inhibition of electrically stimulated rat (Yousif and Oriowo 1999) and guinea pig airway contraction (Yoshihara et al 2004(Yoshihara et al , 2005 is CB 2 -receptor mediated. A CB 2 receptor has also been implicated in the inhibition of capsaicin-induced bronchoconstriction in some studies (Patel et al 2003;Yoshihara et al 2004Yoshihara et al , 2005.…”

Section: Other Peripheral Effectsmentioning

confidence: 98%

“…This profile is not only important with respect to the therapeutic use of this drug but also for basic research, as the effects of cannabinoids such as anandamide or Δ 9 -tetrahydrocannabinol may not always occur via cannabinoid receptors and may also involve, e.g., vanilloid receptors (Nieri et al 2003), the so-called endothelial cannabinoid receptor , metabolism to prostanoids (Grainger and BoachieAnsah 2001; Pratt et al 1998), or other, poorly defined, targets (Carrier et al 2006;Kenny et al 2002;White et al 2001). However, rimonabant acts at noncannabinoid targets only at very high concentrations (White and Hiley 1998).…”

Section: Direct Effects On Cannabinoid and Other Receptorsmentioning

confidence: 99%

See 1 more Smart Citation

Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716)

Diepen

Schlicker

Michel

2008

Naunyn-Schmied Arch Pharmacol

View full text Add to dashboard Cite

Rimonabant is an inverse agonist specific for cannabinoid receptors and selective for their cannabinoid-1 (CB 1 ) subtype. Although CB 1 receptors are more abundant in the central nervous system, rimonabant has many effects in the periphery, most of which are related to prejunctional modulation of transmitter release from autonomic nerves. However, CB 1 receptors are also expressed in, e.g., adipocytes and endothelial cells. Rimonabant inhibits numerous cardiovascular cannabinoid effects, including the decrease of blood pressure by central and peripheral (cardiac and vascular) sites of action, with the latter often being endothelium dependent. Rimonabant may also antagonize cannabinoid effects in myocardial infarction and in hypotension associated with septic shock or liver cirrhosis. In the gastrointestinal tract, rimonabant counteracts the cannabinoid-induced inhibition of secretion and motility. Although not affecting most cannabinoid effects in the airways, rimonabant counteracts inhibition of smoothmuscle contraction by cannabinoids in urogenital tissues and may interfere with embryo attachment and outgrowth of blastocysts. It inhibits cannabinoid-induced decreases of intraocular pressure. Rimonabant can inhibit proliferation of, maturation of, and energy storage by adipocytes. Among the many cannabinoid effects on hormone secretion, only some are rimonabant sensitive. The effects of rimonabant on the immune system are not fully clear, and it may inhibit or stimulate proliferation in several types of cancer. We conclude that direct effects of rimonabant on adipocytes may contribute to its clinical role in treating obesity. Other peripheral effects, many of which occur prejunctionally, may also contribute to its overall clinical profile and lead to additional indications as well adverse events.

show abstract

Section: Other Peripheral Effectsmentioning

confidence: 98%

Section: Direct Effects On Cannabinoid and Other Receptorsmentioning

confidence: 99%

Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716)

Diepen

Schlicker

Michel

2008

Naunyn-Schmied Arch Pharmacol

View full text Add to dashboard Cite

show abstract

“…The endocannabinoid system is a ubiquitous complex signaling network with many biological activities both in the central and peripheral tissues (Hillard, 2015;Maccarrone et al, 2015;Minocci et al, 2011;Nieri et al, 2003a;2003b). It is composed by endogenous ligands (anandamide and 2--arachidonoyglycerol), cannabinoid receptors type--1 (CB1) and type--2 (CB2), enzymes involved in endocannabinoid biosynthesis and metabolism, and more recently discovered members (Di Marzo, 2009).…”

Section: Introductionmentioning

confidence: 99%

Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells

Carpi

Fogli

Polini

et al. 2017

Toxicology in Vitro

Self Cite

View full text Add to dashboard Cite

“…Yawning stimulation by pilocarpine has been antagonized by acute administration of Delta(8)-THC and Delta(9)-THC [27]. But neither CB 1 nor CB 2 receptors have modulated acetylcholine release in guinea-pig trachea [22]. Pretreatment with JTE 907 (a CB 2 receptor inverse agonist) has not influenced the potency of acetylcholine-evoked contraction in the presence of anandamide [25].…”

mentioning

confidence: 98%

“…The analgesic properties of muscarinic receptor agonists have been established as well [19]. A number of studies regarding the muscarinic cholinergic receptor modulators, CB receptor and specific CB 2 receptors interactions have been reported e. g., saliva secretion [20], basal [3H]acetylcholine release, in both guinea-pig ileum [21] and trachea [22], muscle contractions of mouse ileum [23] guinea-pig [24] and human [25] colon, long-term potentiation (LTP) at cerebellar parallel fiber-Purkinje cell synapses [26] and yawning [27]. In our previous study, the influence of interacerebroventricular (i.c.v.)…”

mentioning

confidence: 99%

The Effect of Muscarinic Receptor Modulators on the Antinociception Induced by CB2 Receptor Agonist, JWH133 in Mice

et al. 2016

View full text Add to dashboard Cite

There is no published study regarding the interaction between muscarinic receptor modulators and antinociception induced by cannabinoid receptor (CB) agonist. The effect of pilocarpine (a muscarinic agonist) and atropine (a muscarinic antagonist) on JWH-133 (a CB agonist) induced analgesia in mice was studied. First the analgesic effect of JWH-133 (0.001-1 mg/Kg) or pilocarpine (2.5-20 mg/kg) or atropine (0.2-5 mg/kg) was evaluated. Subsequently, the effect of co-administration of pilocarpine (2.5 mg/kg) or atropine (5 mg/kg) and JWH-133 (0.001-1 mg/Kg) were studied too. JWH-133 and pilocarpine provoked antinociception in mice but atropine did not. Pilocarpine potentiated the analgesic effect of JWH-133 but atropine antagonized that. It can be concluded that JWH-133 induced antinociception is affected by muscarinic receptor modulators in mice.

show abstract

R(+)-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors

Cited by 10 publications

References 49 publications

Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716)

Prejunctional and peripheral effects of the cannabinoid CB1 receptor inverse agonist rimonabant (SR 141716)

Tumor-promoting effects of cannabinoid receptor type 1 in human melanoma cells

The Effect of Muscarinic Receptor Modulators on the Antinociception Induced by CB2 Receptor Agonist, JWH133 in Mice

Contact Info

Product

Resources

About